Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib
Deciphera Pharmaceuticals LLC
In this trial, patients will be randomised to receive 150mg
of oral DCC-2618 or 50mg of oral sunitinib daily.
To join this trial, patients must have a histologic diagnosis of GIST and have progressed on imatinib or have documented intolerance to imatinib therapy.